Regulatory Submission in Europe in Absence of Reference product [Regulatives / Guidelines]

posted by dshah  – India, 2021-03-23 10:51 (1399 d 18:05 ago) – Posting: # 22290
Views: 7,598

Hi Abhay Patil!
In absence of Innovator product in EU and UK market for FDC, you may have to do BE against individual drug substance innovator product. Please see Guideline on clinical development of fixed combination medicinal products.
Regards,
Dshah

Complete thread:

UA Flag
Activity
 Admin contact
23,363 posts in 4,906 threads, 1,678 registered users;
158 visitors (0 registered, 158 guests [including 17 identified bots]).
Forum time: 04:56 CET (Europe/Vienna)

The combination of some data and an aching desire
for an answer does not ensure that a reasonable answer
can be extracted from a given body of data.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5